Background The aim of this study was to develop comprehensive and effective nomograms for predicting overall survival (OS) and cancer-specific survival (CSS) rates in patients with colorectal mucinous adenocarcinoma (CRMA). Methods A total of 4711 CRMA patients who underwent radical surgery between 2010 and 2018 from the Surveillance, Epidemiology, and End Results (SEER) database were collected and randomized into development (n=3299) and validation (n=1412) cohorts at a ratio of 7:3 for model development and validation. OS and CSS nomograms were developed using the prognostic factors from the development cohort after multivariable Cox regression analysis. The performance of the nomograms was evaluated using Harrell’s concordance index (C-index), calibration diagrams, receiver operating characteristic (ROC) curves, and decision curve analysis (DCA). Results The study included 4711 patients. Multivariate Cox regression analysis demonstrated that age, tumor size, grade, pT stage, pN stage, M stage, carcinoembryonic antigen, perineural invasion, tumor deposits, regional nodes examined, and chemotherapy were correlated with OS and CSS. Marital status was independently related to OS. In the development and validation cohorts, the C-index of OS was 0.766 and 0.744, respectively, and the C-index of CSS was 0.826 and 0.809, respectively. Calibration curves and ROC curves showed predictive accuracy. DCA showed that the nomograms had excellent potency over the 8th edition of the TNM staging system with higher clinical net benefits. Significant differences in OS and CSS were observed among low-, medium-, and high-risk groups. Conclusions Nomograms were developed for the first time to predict personalized 1-, 3-, and 5-year OS and CSS in CRMA postoperative patients. External and internal validation confirmed the excellent discrimination and calibration ability of the nomograms. The nomograms can help clinicians design personalized treatment strategies and assist with clinical decisions.
BackgroundThe aim of this study was to develop comprehensive and effective nomograms for predicting overall survival (OS) and cancer-specific survival (CSS) rates in patients with colorectal mucinous adenocarcinoma (CRMA). MethodsA total of 4711 CRMA patients who underwent radical surgery between 2010 and 2018 from the Surveillance, Epidemiology, and End Results (SEER) database were collected and randomized into development (n=3,299) and validation (n=1,412) cohorts at a ratio of 7:3 for model development and validation. OS and CSS nomograms were developed using the prognostic factors from the development cohort after multivariable Cox regression analysis. The performance of the nomograms was evaluated using Harrell’s concordance index (C-index), calibration diagrams, receiver operating characteristic (ROC) curves, and decision curve analysis (DCA).ResultsThe study included 4,711 patients. Multivariate Cox regression analysis demonstrated that age, tumor size, grade, pT stage, pN stage, M stage, carcinoembryonic antigen, perineural invasion, tumor deposits, regional nodes examined, and chemotherapy were correlated with OS and CSS. Marital status was independently related to OS. In the development and validation cohorts, the C-index of OS was 0.766 and 0.744, respectively, and the C-index of CSS was 0.826 and 0.809, respectively. Calibration curves and ROC curves showed predictive accuracy. DCA showed that the nomograms had excellent potency over the 8th edition of TNM staging system with higher clinical net benefits. Significant differences in OS and CSS were observed among low-, medium-, and high-risk groups.ConclusionsNomograms were developed for the first time to predict personalized 1-, 3-, and 5-year OS and CSS in CRMA postoperative patients. External and internal validation confirmed the excellent discrimination and calibration ability of the nomograms. The nomograms can help clinicians design personalized treatment strategies and assist with clinical decisions.
Background: Gastric cancer (GC) is one of the most common cancers in the world. Patients with GC who experienced early relapse have poor prognosis. We aim to develop an early relapse-associated gene signature to optimize prognosis prediction in patients with replapsing GC. Methods: The GC cohorts including GSE62254 set (N=300) and GSE15459 set (N=192) were extracted from Gene Expression Omnibus (GEO) database. Propensity score matching (1:1) based on pathological stage was executed between patients with early relapse and long-term survival from GSE62254 set. Global transcriptome analysis was performed between the two groups to identify early relapse-associated gene. Based on the differentially expressed genes, we developed a classifier incorporating 5 genes that using LASSO Cox regression model. The signature’s prognostic value was internally validated in 210 GC patients and validated in GSE15459 set externally. The patients from GSE62254 set could be divided into high-risk or low-risk group.Results: In the train set, patients in high-risk group had poor prognosis as compared to those in low-risk group [hazard ratio (HR): 3.002, 95% confidence interval (CI): 2.132-4.226, P<0.001)]. Good reproducibility for the prognostic value of early relapse-associated gene signature was verified in the internal validation set (HR: 2.772, 95% CI: 1.836–4.184, P<0.001) and another external validation set (HR: 1.733, 95% CI: 1.149–2.614, P=0.009). Also, we developed a nomogram which integrated the five mRNA classifier, pathological stage and lymph node ratio (LNR) to evaluate prognosis based on GSE62254 set. Time-dependent receiver-operating characteristic at 1 year demonstrated that integrated signature had better prognostic accuracy [area under curve (AUC=0.849)] than the American Joint Commission on Cancer TNM staging system (AUC=0.773) and LNR (AUC=0.811) in GSE62254 set. Conclusions: This study suggest that an early relapse-associated gene signature that can robustly divide gastric cancer patients into two groups with distinctive prognosis. This classifier may contribute to select gastric cancer patients with poor prognosis who require more frequent follow-up and more aggressive therapeutic intervention.
Purpose Gastric mucinous adenocarcinoma (MGC) is an uncommon and special malignant tumor. There is currently no research has been conducted on MGC patient survival risk factors. Hence, the objective of this study was to develop and validate a prognostic prediction model for predicting survival outcomes in MGC patients. Methods A total of 586 patients diagnosed with MGC between 2004 and 2015 were extracted from the SEER database. Using univariate and multivariate Cox proportional regression models, independent prognostic factors for overall survival (OS) in MGC patients were identified. Based on these factors, a prognostic model for MGC was established. The prediction accuracy and reliability of the novel model were evaluated utilizing concordance-index (C-index), calibration curve, receiver-operator-curve (ROC) and clinicaldecision-curve-analysis (DCA). Results Multivariate Cox regression analysis revealed that age at diagnosis, marital status, pT stage, M, surgery status, radiotherapy and chemotherapy are independent influencing factors of OS in patients with MGC. The model C-index and the area-under-the-curve (AUC) values indicted a high level of differentiation. The calibration curve also demonstrates that the predicted values and actual observed values are in good correlation. Additionally, the DCA curve demonstrates that the nomogram is vastly superior to the 8th edition of the TNM staging system, has superior predictive performance, and is more clinically applicable. Conclusions The prediction model constructed and validated for the first time has exceptional prediction performance, can accurately estimate the OS of MGC patients, has a certain reference value for clinical patients, and is beneficial to the management of clinical patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.